OSE Immunotherapeutics : Financial visibility out to 2027 at least
>Robust financial position - OSE yesterday released its H1 2024 results. Operating income came to € 82m (vs -€ 11.8m in H1 2023), stemming mainly from revenues from the collaborations with AbbVie and Boehringer. Opex increased to € 19.3m (vs € 14.9m in H1 2023) of which 77% was dedicated to R&D (€ 13.8m). Net income was € 57.2m. At the balance sheet level, several actions helped consolidated the company’s cash position, namely the payments under the agreements wi...Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.